Picture of Adalta logo

1AD — Adalta Share Price

0.000.00%
au flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-17.41%
3m-25.21%
6m-26.39%
1yr-60.63%
Volume Change (%)
10d/3m+17.93%
Price vs... (%)
52w High-64.58%
50d MA-17.68%
200d MA-29.12%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-73.22%
Return on Equity-70.13%
Operating Margin-119.13%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202230th Jun 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Adalta EPS forecast chart

Profile Summary

AdAlta Limited is an Australia-based clinical-stage biotechnology company. The principal business of the Company is the discovery and development of protein-based therapeutic and diagnostic products using its i-body platform. The Company has four active development programs ranging from discovery to Phase I clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product candidate, AD-214, is being developed as a anti-fibrotic therapeutic focusing initially on the degenerative and fatal orphan disease, Idiopathic Pulmonary Fibrosis (IPF) and related Interstitial Lung Diseases (ILDs), and with potential in other fibrotic diseases, particularly of the eye and kidney, and certain cancers. Its internal pipeline is focused on G-Protein Coupled Receptors (GPCRs) implicated in fibrotic and inflammatory diseases and cancer, and its external pipeline is leveraging partner expertise to pursue a range of targets and indications.

Directors

Last Annual
June 30th, 2021
Last Interim
December 31st, 2021
Incorporated
June 22nd, 2006
Public Since
August 22nd, 2016
No. of Shareholders
1,541
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
au flag iconAustralian Stock Exchange - SEATS
Shares in Issue
297,014,806
Blurred out image of a map
Address
Shop 14 330 Collins St, MELBOURNE, 3000
Web
http://www.adalta.com.au/
Phone
+61 394795159
Auditors
Butler Settineri (Audit) Pty Ltd

1AD Share Price Performance

Upcoming Events for 1AD

Full Year 2022 Adalta Ltd Earnings Release

Similar to 1AD

Picture of Actinogen Medical logo

Actinogen Medical

au flag iconAustralian Stock Exchange - SEATS

Picture of Alterity Therapeutics logo

Alterity Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Amplia Therapeutics logo

Amplia Therapeutics

au flag iconAustralian Stock Exchange - SEATS

Picture of Anatara Lifesciences logo

Anatara Lifesciences

au flag iconAustralian Stock Exchange - SEATS

Picture of Anteotech logo

Anteotech

au flag iconAustralian Stock Exchange - SEATS

FAQ

Or unlock with your email

Or unlock with your email